Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$23.50 USD
+0.76 (3.34%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $23.51 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STOK 23.50 +0.76(3.34%)
Will STOK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Other News for STOK
The technical outlook for STOK is unchanged after it falls 1.81% on September 18
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc
STOK forms Boomer Buy Setup on September 16
STOK forms Upper Bollinger Band Walk on September 15
Tracking Baker Brothers Portfolio - Q2 2025 Update